Please wait while the formulary information is being retrieved.
MIDOL (NAPROXEN SODIUM)
500 mg-25 mg tablet
- Dosage information is not available
Max St Menstrual 500 mg-60 mg-15 mg tablet
- Dosage information is not available
500 mg-60 mg-15 mg tablet
- Dosage information is not available
500 mg-60 mg-15 mg tablet
- Dosage information is not available
- dipyridamole
Contraindicated
- Acid Reducer (cimetidine)
- Acid Relief (cimetidine)
- Adenocard
- Adenoscan
- adenosine
- adenosine (diagnostic)
- cimetidine
- Curad Enema
- Disposable Enema
- Enema
- Enema Disposable
- Fleet Enema
- Fleet Enema Extra
- Fleet Pediatric
- Heartburn Relief
- Lexiscan
- Oral Saline Laxative
- Osmoprep
- Phosphate Laxative
- Preparation Cleansing
- Ready-to-use Enema
- Reclast
- regadenoson
- sod phos mono-sod phos dibasic
- sodium phosphates
- Tagamet Hb
- zoledronic acid
- zoledronic acid-mannitol-water
- Zometa
Severe
Moderate
- Coumadin
- fluvoxamine
- isoniazid
- isoniazid-rifamp-pyrazinamide
- Jantoven
- lithium carbonate
- lithium citrate
- Lithobid
- Luvox Cr
- Rifamate
- rifampin-isoniazid
- Rifater
- warfarin
- 30 day risk period post-myocardial infarction
- Acetaminophen overdose
- Acute hepatic failure
- Acute hepatitis C
Contraindicated
- Angle-closure glaucoma
- Benign prostatic hyperplasia
- Bladder outflow obstruction
- Chronic idiopathic constipation
- Disease of liver
- Necrotizing enterocolitis
- Peptic ulcer
- Protein-calorie malnutrition
- Severe renal impairment
- Shock
- Stenosing peptic ulcer
- Urinary retention
Severe
Moderate
- Cardiac arrhythmia
- Hypertension
- Hyperthyroidism
- Insomnia
- Ocular hypertension
- Renal disease with moderate to severe impairment
- Seizure disorder
- Severe hepatic disease
MIDOL (NAPROXEN SODIUM)
- None
- Abdominal pain with cramps
- Drowsy
- Gastrointestinal irritation
- Insomnia
- Nervousness
- Thick bronchial secretions
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Excitement
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute generalized exanthematous pustulosis
- Acute hepatic failure
- Agranulocytosis
- Allergic dermatitis
- Angioedema
- Blood dyscrasias
- Drug-induced hepatitis
- Extrasystoles
- Laryngeal edema
- Leukopenia
- Maculopapular rash
- Neutropenic disorder
- Stevens-johnson syndrome
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
Less Severe
- Acute confusion
- Agitation
- Anorexia
- Blurred vision
- Dizziness
- Dry nose
- Dry throat
- Dysuria
- Erythema
- Excitement
- Hyperesthesia
- Hyperglycemia
- Hyperhidrosis
- Irritability
- Medication overuse headache
- Nausea
- Nephrotoxicity
- Nervousness
- Nightmares
- Scotomata
- Skin photosensitivity
- Skin rash
- Symptoms of anxiety
- Tachycardia
- Tinnitus
- Tremor
- Urticaria
- Visual changes
- Vomiting
- Xerostomia
Contraindicated
Pyrilamine
Possible CNS excitation and seizure risk in newborns.
Do not use in pediatrics <6 years of age unless clinician consultation.
- 1 Day – 29 Days
- 1 Possible CNS excitation and seizure risk in newborns.
- 1 Do not use in pediatrics <6 years of age unless clinician consultation.
- 30 Days – 6 Years
- 1 Possible CNS excitation and seizure risk in newborns.
- 1 Do not use in pediatrics <6 years of age unless clinician consultation.
Severe Precaution
None
Management or Monitoring Precaution
Acetaminophen (oral,rectal)
Use weight based dosing in children less than 12 years.
Caution in: seizure disorder, cardiovascular disease, or in premature neonates with renal or hepatic impairment.
Adverse CNS effects of insomnia, restlessness, nervousness, and mild delirium, more severe in children.
Consult clinician prior to use. Limited safety data,
- 1 Day – 12 Years
- Use weight based dosing in children less than 12 years.
- 1 Day – 364 Days
- Use weight based dosing in children less than 12 years.
- 1 Years – 13 Years
- Use weight based dosing in children less than 12 years.
- 1 Day – 18 Years
- Use weight based dosing in children less than 12 years.
Caffeine
Use weight based dosing in children less than 12 years.
Caution in: seizure disorder, cardiovascular disease, or in premature neonates with renal or hepatic impairment.
Adverse CNS effects of insomnia, restlessness, nervousness, and mild delirium, more severe in children.
Consult clinician prior to use. Limited safety data,
- 1 Day – 12 Years
- Caution in: seizure disorder, cardiovascular disease, or in premature neonates with renal or hepatic impairment.
- Adverse CNS effects of insomnia, restlessness, nervousness, and mild delirium, more severe in children.
- 1 Day – 364 Days
- Caution in: seizure disorder, cardiovascular disease, or in premature neonates with renal or hepatic impairment.
- Adverse CNS effects of insomnia, restlessness, nervousness, and mild delirium, more severe in children.
- 1 Years – 13 Years
- Caution in: seizure disorder, cardiovascular disease, or in premature neonates with renal or hepatic impairment.
- Adverse CNS effects of insomnia, restlessness, nervousness, and mild delirium, more severe in children.
- 1 Day – 18 Years
- Caution in: seizure disorder, cardiovascular disease, or in premature neonates with renal or hepatic impairment.
- Adverse CNS effects of insomnia, restlessness, nervousness, and mild delirium, more severe in children.
Pamabrom
Use weight based dosing in children less than 12 years.
Caution in: seizure disorder, cardiovascular disease, or in premature neonates with renal or hepatic impairment.
Adverse CNS effects of insomnia, restlessness, nervousness, and mild delirium, more severe in children.
Consult clinician prior to use. Limited safety data,
- 1 Day – 12 Years
- Consult clinician prior to use. Limited safety data,
- 1 Day – 364 Days
- Consult clinician prior to use. Limited safety data,
- 1 Years – 13 Years
- Consult clinician prior to use. Limited safety data,
- 1 Day – 18 Years
- Consult clinician prior to use. Limited safety data,
Acetaminophen
- Severity Level:
2
- Additional Notes: Available data suggest no known risk; otc product, no fda pregnancy warnings
Caffeine
- Severity Level:
C
- Additional Notes: Reports of miscarriage,poor fetal growth possibly assoc w/high doses of caffeine
Pyrilamine
- Severity Level:
2
- Additional Notes: No fda category; incr risk of retrolental fibroplasia seen in premature infants
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Caffeine
High doses may cause hyperactivity and wakefulness in infant.
Use is not recommended; may cause unusual excitement or irritability
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Drug shown to have adverse effect | High doses may cause hyperactivity and wakefulness in infant. |
Pyrilamine
High doses may cause hyperactivity and wakefulness in infant.
Use is not recommended; may cause unusual excitement or irritability
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Drug shown to have adverse effect | Use is not recommended; may cause unusual excitement or irritability |
No Known Risk
Acetaminophen
Low levels excreted with low risk for adverse effects in infant
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | No adverse effect | Low levels excreted with low risk for adverse effects in infant |
Contraindicated
None
Precaution Exists
Acetaminophen (oral,rectal)
Hepatic-Elderly may be more susceptible to hepatotoxicity. Strict adherence to a maximum daily dose is recommended, and the maximum dose recommendation varies between 3000-3800 mg depending on strength used and source of the recommendation.
Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating antihistamine preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
Pyrilamine
Hepatic-Elderly may be more susceptible to hepatotoxicity. Strict adherence to a maximum daily dose is recommended, and the maximum dose recommendation varies between 3000-3800 mg depending on strength used and source of the recommendation.
Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating antihistamine preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- None
Formulary Reference Tool